The potent BACE1 inhibitor LY2886721 elicits robust central Aβ pharmacodynamic responses in mice, dogs, and humans
about
Current Research Therapeutic Strategies for Alzheimer's Disease TreatmentPresumed LRP1-targeting transport peptide delivers β-secretase inhibitor to neurons in vitro with limited efficiencyThree Dimensional Human Neuro-Spheroid Model of Alzheimer's Disease Based on Differentiated Induced Pluripotent Stem CellsChemoproteomic profiling reveals that cathepsin D off-target activity drives ocular toxicity of β-secretase inhibitorsBACE1 across species: a comparison of the in vivo consequences of BACE1 deletion in mice and ratsFuture Therapeutics in Alzheimer's Disease: Development Status of BACE Inhibitors.A novel BACE inhibitor NB-360 shows a superior pharmacological profile and robust reduction of amyloid-β and neuroinflammation in APP transgenic mice.Amyloid β-protein oligomers upregulate the β-secretase, BACE1, through a post-translational mechanism involving its altered subcellular distribution in neuronsTargeting the BACE1 Active Site Flap Leads to a Potent Inhibitor That Elicits Robust Brain Aβ Reduction in RodentsAZD3293: A Novel, Orally Active BACE1 Inhibitor with High Potency and Permeability and Markedly Slow Off-Rate Kinetics.A Review of Fluid Biomarkers for Alzheimer's Disease: Moving from CSF to Blood.BACE inhibition-dependent repair of Alzheimer's pathophysiology.α-Mangostin decreases β-amyloid peptides production via modulation of amyloidogenic pathway.Preclinical to phase II amyloid beta (Aβ) peptide modulators under investigation for Alzheimer's disease.The road to restoring neural circuits for the treatment of Alzheimer's disease.The BACE1 inhibitor verubecestat (MK-8931) reduces CNS β-amyloid in animal models and in Alzheimer's disease patients.A digital enzyme-linked immunosorbent assay for ultrasensitive measurement of amyloid-β 1-42 peptide in human plasma with utility for studies of Alzheimer's disease therapeutics.Dogs with Cognitive Dysfunction as a Spontaneous Model for Early Alzheimer's Disease: A Translational Study of Neuropathological and Inflammatory Markers.APP mouse models for Alzheimer's disease preclinical studies.Re-evaluation of soluble APP-α and APP-β in cerebrospinal fluid as potential biomarkers for early diagnosis of dementia disorders.Beta secretase activity in peripheral nerve regeneration.Clinical Bioavailability of the Novel BACE1 Inhibitor Lanabecestat (AZD3293): Assessment of Tablet Formulations Versus an Oral Solution and the Impact of Gastric pH on Pharmacokinetics.Cerebrospinal fluid and blood biomarkers for neurodegenerative dementias: An update of the Consensus of the Task Force on Biological Markers in Psychiatry of the World Federation of Societies of Biological Psychiatry.A simplified and sensitive method to identify Alzheimer's disease biomarker candidates using patient-derived induced pluripotent stem cells (iPSCs).Beta-secretase inhibitors in phase I and phase II clinical trials for Alzheimer's disease.BACE1 inhibition more effectively suppresses initiation than progression of β-amyloid pathology.Synthesis of amino heterocycle aspartyl protease inhibitors.BACE1 Inhibitor Lanabecestat (AZD3293) in a Phase 1 Study of Healthy Japanese Subjects: Pharmacokinetics and Effects on Plasma and Cerebrospinal Fluid Aβ Peptides.AZD3293: Pharmacokinetic and Pharmacodynamic Effects in Healthy Subjects and Patients with Alzheimer's Disease.The Role of microRNAs in Alzheimer's Disease and Their Therapeutic Potentials.Highlights in BACE1 Inhibitors for Alzheimer's Disease Treatment.The BACE-1 inhibitor CNP520 for prevention trials in Alzheimer's disease
P2860
Q26765530-F3ED3848-A3DB-4FBE-8310-91396345CF60Q27341864-FB3EE102-1E8C-4E04-8E6E-37705DA5C8B8Q28554402-72F07B79-2ECF-4526-92EB-0AA0E79F1CE3Q28822108-07CA6F72-2088-4853-95E6-50A2A9B6B90EQ30361192-D02C453B-D289-49D3-8EDA-70BD4CD924FBQ35972878-7AF31F75-E708-4D90-949B-F447C84BD47AQ36027275-33BC14D6-80F5-43EC-A81C-F86ADCD0A4C4Q36263251-8F0E388B-FEBD-42E8-B918-E0D2CE901744Q36681717-F5EC60BA-A060-442F-B767-FFCB0F3673D7Q37053876-75210326-F936-4E71-B273-7599E8E1D8D3Q38653401-A35A0E3B-0596-47AE-B0E7-491A1F607C31Q38663691-9F035B65-4D34-4AE3-8176-1FC86A593C80Q38827287-797F23B8-9EC8-4D28-ABA7-AB3899A6D747Q38864839-552324B0-62FC-4C08-9836-196744C7C2B1Q39004340-5E26603C-1EAF-44C7-887F-CCC35E997F94Q39222469-ADCA077C-4D2D-41D8-B728-69370E1DE549Q40428596-D0070E8E-233E-49FC-94F7-F77F0ED6D1FAQ40839177-852CD442-3D36-426C-92E4-5E392F092656Q41582196-CABF0B4A-79B8-4177-A2EF-7F102BB7A6BBQ42118491-0D8309E9-1602-4776-868A-0E49DF082295Q47368687-ECD0A08E-0067-4189-9C7F-5D5E4696A98CQ47555674-2C646F14-1537-4C1D-BD08-35F934BB2B97Q47587631-302E2D77-D36E-44D4-A15B-93DC3335F751Q47677020-39E57366-48B0-43EF-8BC3-E1CBDD0177E3Q47940819-EA4C587A-2B22-4C47-8DF1-90345A229FD2Q50074018-13987ED4-944C-4600-A3BA-DBF113B884B6Q50856369-36D16D2C-FDD0-4D79-A270-3A31EE1EBF53Q50943210-558CE5C0-0631-414C-84BC-7A3F5C61E0B0Q51371177-FF28FEF3-F3E9-45C0-9A34-6831BD3C5AF4Q51760979-BEC49E47-5F1F-4FEE-95DE-0EB4934B1091Q54940167-8956A97B-FCED-4CD1-B6EB-AB2D99F6CE18Q59133137-5AD7BF2B-5C4C-49FB-8753-B873B6F9E84E
P2860
The potent BACE1 inhibitor LY2886721 elicits robust central Aβ pharmacodynamic responses in mice, dogs, and humans
description
2015 nî lūn-bûn
@nan
2015 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2015 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
name
The potent BACE1 inhibitor LY2 ...... nses in mice, dogs, and humans
@ast
The potent BACE1 inhibitor LY2 ...... nses in mice, dogs, and humans
@en
The potent BACE1 inhibitor LY2 ...... nses in mice, dogs, and humans
@nl
type
label
The potent BACE1 inhibitor LY2 ...... nses in mice, dogs, and humans
@ast
The potent BACE1 inhibitor LY2 ...... nses in mice, dogs, and humans
@en
The potent BACE1 inhibitor LY2 ...... nses in mice, dogs, and humans
@nl
prefLabel
The potent BACE1 inhibitor LY2 ...... nses in mice, dogs, and humans
@ast
The potent BACE1 inhibitor LY2 ...... nses in mice, dogs, and humans
@en
The potent BACE1 inhibitor LY2 ...... nses in mice, dogs, and humans
@nl
P2093
P50
P3181
P1476
The potent BACE1 inhibitor LY2 ...... nses in mice, dogs, and humans
@en
P2093
Anthony R Borders
Brian M Mathes
Brian M Watson
Celedon R Gonzales
David E Timm
David O Calligaro
Douglas E James
Ferenc Martényi
Grant M Vaught
Jon A Erickson
P304
P3181
P356
10.1523/JNEUROSCI.4129-14.2015
P407
P577
2015-01-01T00:00:00Z